Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

PrismRA results informing selection of TNFi vs non-TNFi treatment was associated with better CDAI outcomes compared to matched external comparator patients. PrismRA testing helps fill the need for a precision medicine approach to more rapidly identify the most effective therapy for individual patients with RA.